Rectify And Boehringer Ingelheim Collaborate To Advance First-In-Class Treatments For Chronic Kidney Disease
Dec 22 (Reuters) -
RECTIFY AND BOEHRINGER INGELHEIM COLLABORATE TO ADVANCE FIRST-IN-CLASS TREATMENTS FOR CHRONIC KIDNEY DISEASE
RECITIFY: WILL RECEIVE UPFRONT PAYMENT, POTENTIAL TO EARN UP TO $448 MILLION THROUGH MILESTONES & ROYALTIES
Further company coverage: [ ]
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.